NEUROCRINE BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
NEUROCRINE BIOSCIENCES INC (NBIX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $7.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $7.20M, a 132.26% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $3.10M, a 138.46% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $1.30M.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $7.20M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $3.10M 10-K · filed 2026-02-11 | |
| 2022-12-31 | $1.30M 10-K · filed 2025-02-10 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-09 | -$200.00K 10-K · filed 2022-02-11 |
| 2020-12-31 | $500.00K 10-K · filed 2023-02-09 | -$100.00K 10-K · filed 2021-02-05 |
| 2019-12-31 | $300.00K 10-K · filed 2022-02-11 | $257.00K 10-K · filed 2020-02-07 |
| 2018-12-31 | -$300.00K 10-K · filed 2021-02-05 | -$257.00K 10-K · filed 2019-02-08 |
| 2017-12-31 | -$956.00K 10-K · filed 2020-02-07 | |
| 2016-12-31 | $211.00K 10-K · filed 2019-02-08 | |
| 2015-12-31 | $53.00K 10-K · filed 2018-02-13 | |
| 2014-12-31 | $79.00K 10-K · filed 2017-02-14 | |
| 2013-12-31 | $40.00K 10-K · filed 2016-02-11 | |
| 2012-12-31 | -$42.00K 10-K · filed 2015-02-09 | |
| 2011-12-31 | -$29.00K 10-K · filed 2014-02-11 | |
| 2010-12-31 | $38.00K 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |